Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From The Norwegian Mother and Child Cohort Study
- 13 April 2010
- journal article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 50 (4) , 563-575
Abstract
( Headache 2010;50:563‐575) Objective.— To evaluate the safety of triptan therapy during pregnancy. Background.— Information on the safety of triptan therapy during pregnancy is scarce and only available for sumatriptan, naratriptan, and rizatriptan. No associations with congenital malformations have been detected so far, but one study found a significant association between sumatriptan exposure during pregnancy and prematurity. Methods.— The study population consisted of 69,929 pregnant women and their newborn children for whom data on drug exposure and pregnancy outcome were available. Information on triptan therapy and potential socio‐demographic and medical confounding factors was obtained from the Norwegian Mother and Child Cohort Study. Information on congenital malformations and other adverse pregnancy outcomes was obtained from the Norwegian Medical Birth Registry. The datasets were linked via the women's personal identification number. Pearson's χ 2 tests and logistic regression analyses were used to identify associations between triptan therapy and pregnancy outcome. Results.— No significant associations between triptan therapy during the first trimester and major congenital malformations (unadjusted OR: 1.0; 95% CI 0.8‐1.3, adjusted OR: 1.0; 95% CI 0.7‐1.2) or other adverse pregnancy outcomes were found. Triptan therapy during the second and/or third trimesters was significantly associated with atonic uterus (unadjusted OR: 1.5; 95% CI 1.1‐1.9, adjusted OR: 1.4; 95% CI 1.1‐1.8), and blood loss >500 mL during labor (unadjusted OR: 1.3; 95% CI 1.1‐1.5, adjusted OR: 1.3; 95% CI 1.1‐1.5). Conclusions.— Triptan therapy during pregnancy was not associated with an overall increased risk of congenital malformations. It cannot, however, be excluded that a difference in the risk between triptan use and individual or rare congenital malformations may exist. A slight increase in the risk of atonic uterus and hemorrhage was associated with triptan use during the second and/or third trimesters. Although the present findings are reassuring, confirmation in independent studies is warranted.Keywords
This publication has 40 references indexed in Scilit:
- The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?Headache: The Journal of Head and Face Pain, 2009
- Characterization of Serotonin Receptors in Pregnant Human MyometriumThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Serotonin and migraine: a reconsideration of the central theoryThe Journal of Headache and Pain, 2008
- Epidemiology and comorbidity of headacheThe Lancet Neurology, 2008
- Headache and PregnancyThe Neurologist, 2008
- Triptans in PregnancyTherapeutic Drug Monitoring, 2008
- Migraine Headaches and Preeclampsia: An Epidemiologic ReviewHeadache: The Journal of Head and Face Pain, 2006
- Risk of preeclampsia in relation to maternal history of migraine headachesThe Journal of Maternal-Fetal & Neonatal Medicine, 2005
- Headache During PregnancyCephalalgia, 1997
- Migraine Without Aura and Reproductive Life Events: A Clinical Epidemiological Study in 1300 WomenHeadache: The Journal of Head and Face Pain, 1993